Repeat SLT Effective in LiGHT Trial


■ A subset of 115 eyes in 90 medication-naive OAG and OHT patients in the Laser in Glaucoma and Ocular Hypertension (LiGHT) trial received repeat 360° SLT within 18 months after receiving initial SLT at baseline. Retreatment was triggered by predefined IOP and disease-progression criteria. Repeat SLT maintained drop-free IOP control in 67% of 115 eyes at 18 months, with no clinically relevant adverse events.

The researchers who conducted the study, which was reported in the journal Ophthalmology, found that these exploratory analyses demonstrate repeat SLT can maintain IOP at or below target IOP in medication-naive OAG and OHT eyes requiring retreatment, with at least an equivalent duration of effect to initial laser.